Macías GE, Hurtado MR, Vargas VP

Language: Spanish
References: 22
Page: 209-213
PDF size: 87.50 Kb.

ABSTRACT

Patient 23-years-old female with Fisher-Evans syndrome diagnosis. The patient received metilprednisolone without complete remission. Splenectomy was done achieving partial response with persistent hemolysis. Anti-CD20 was given at 1g and the patient remains in complete remission for 15 months. Evans syndrome was first described by Evans in 1951 and is characterized by hemolytic anemia with Coombs direct positive and the association to autoimmune thrombocytopenia. First line treatment in Evans syndrome are corticosteroids. Intravenous immunoglobulin, splenectomy, azathioprine, and cyclosporine as well available treatment options. Rituximab (375 mg/m2/dosis), a monoclonal antibody anti-CD20, have shown effectiveness in this group of patients (Evans syndrome), they achieve the complete remission 15 months after completion of therapy. The rare occurrence of this disease and the response to anti-CD20, merit publication.

REFERENCES

1. Evans RS, Takahashi K. Duane RT, Payne R. Primary thrombocytopenic purple and acquired hemolytic anemia: Evidence for a common etiology. AMA Arch Intern Med 1951; 1: 48-65.

2. Mathew, Prasad. Evans Syndrome. www.eMedicine.com, Octubre, 2005.

3. Wang W, Herrad H, Pui C et al. Immunoregulatory abnormalities in Evans syndrome. American Journal of Hematology 1983; 15: 381-390.

4. Savasan S, Warrier I, Ravindranath Y. The Espectrum of Evan’s syndrome. Arch Dis Child 1997; 77(3): 245-248.

5. Norton A, Roberts I. Management of Evans syndrome. British Journal of Hematology 2005; 132: 125-137.

6. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-497.

7. Nuss R, Wang W. Intravenous gammaglobulin for thrombocytopenia in children with Evans syndrome. Am J Pediatr Hematol Oncol 1987; 9(2): 164-167.

8. Font J, Jiménez S, García-Carrasco M et al. Splenectomy for refractory Evan’s syndrome associated with antiphospholipid antibodies: report of two cases. Ann Rheum Dis 2000; 59: 920-923.

9. Lavalle C, Hurtado R, Quezada J et al. Hemocytopenic as inicial manifestation of systemic lupus erythematous. Prognostic significance. Clinical Rheumatology 1983; 2(3): 227-232.

10. Morales-Arias J, Dixon N, Escalon E et al. Favorable response of idiopathic Evans syndrome to rituximab. Inter Pediatrics 2004; 3(19): 170-74.

11. Grossbard ML. Monoclonal antibody-based therapy of cancer. Marcel Dekker Inc. (Ed.), New York 1998.

12. Shenoy S, Nelly M et al. Rituximab therapy in children with chronic refractory immune cytopenia: long term efficacy and immune function analysis. Blood 2003; 102(11): 286.

13. Salopek TG, Logsetty S et al. Anti-CD20 chimeric monoclonal antibody (Rituximab) for the treatment of recalcitrant, life threatening Pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol 2002; 47(5): 785-788.

14. Zecca M, Nobili B, Ramenghi U et al. Rituximab for the treatment of refractory AIHA in children. Blood 2003; 101(10): 3857-3861.

15. Morales-Arias J, Dixon N, Escalon E et al. Favorable response of idiopathic Evans syndrome to rituximab. International Pediatrics 2004; 19(3): 170-174.

16. Grossi A, Santini V, Longo G et al. Treatment with anti CD20 antibodies of patients with autoimmune thrombocytopenia with or without hemolytic anemia: worsening in hemoglobin level. Blood 2000; 96: 1089A.

17. Eisemberg R. Rituximab in lupus. Arthritis Res Ther 2003; 5: 157-159.

18. Andel-Raheem MM, Potti A, Kobrinski N. Severe Evan’s syndrome secondary to interleukin-2 therapy: treatment with chimeric monoclonal anti-CD20 antibody. Ann Hematol 2001; 80: 543-545.

19. Maloney DG, Grillo-López AJ, White CA et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 1997; 90(6): 2188-2195.

20. Mantadakis E, Danilatou V, Stiakaki E, Kalmanti M. Rituximab for refractory Evans syndrome and other immune-mediated hematologic diseases. Am J Hematol 2004; 77(3): 303-310.

21. Stasi R, Pagano A, Stipa E et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purple. Blood 2001; 98: 952-957.

22. Shanafelt TD, Madueme HL, Wolf RC et al. Rituximab for immune cytopenia in adults: immune thrombocytopenic purple, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clin Proc 2003; 78: 1340-1346.